Sandoz Group AG Expands European Biosimilar Production with New Lendava Manufacturing Hub
Sandoz Group AG has announced the inauguration of a high‑volume drug‑substance manufacturing centre in Lendava, Slovenia. The facility, engineered around cutting‑edge automation and process‑analytical technology (PAT), augments the company’s existing biosimilar production footprint in Toulouse and Ljubljana. It is a key milestone in Sandoz’s “Bio100” strategy, which aims to launch more than 100 biosimilar therapies by 2040.
Manufacturing Innovation and Process‑Analytical Technology
The Lendava plant incorporates a fully integrated PAT framework that couples real‑time monitoring of critical quality attributes (CQAs) with advanced process control algorithms. This enables continuous assessment of parameters such as cell‑viability, product titer, host‑cell‑DNA (HCDNA) clearance, and aggregation propensity, all of which are pivotal for ensuring biosimilarity to the reference biologic. By leveraging high‑throughput analytical techniques—including mass spectrometry‑based glyco‑profiling and differential scanning calorimetry—Sandoz can guarantee that the amino‑acid sequence, post‑translational modification (PTM) pattern, and higher‑order structure of its biosimilars align with those of the originator products within the strict equivalence margins defined by regulatory agencies.
The plant’s modular design allows for flexible scale‑up from low‑volume pilot runs to high‑volume commercial production. This scalability is essential for matching production capacity to market demand, particularly for high‑demand molecules such as monoclonal antibodies (mAbs) and recombinant fusion proteins.
Clinical‑Trial Evidence Supporting Sandoz Biosimilars
Sandoz’s biosimilar portfolio spans several therapeutic classes, including oncology, immunology, and metabolic disease. Clinical validation follows the rigorous three‑step pathway mandated by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA):
- Analytical Similarity – Extensive physicochemical and functional assays confirm that the biosimilar and reference product share identical structural and activity profiles.
- Non‑clinical Pharmacology – In vitro and in vivo studies (e.g., receptor binding, ADCC, CDC assays) demonstrate comparable pharmacodynamics and safety signals.
- Clinical Equivalence – Phase III trials, often conducted in a sensitive indication such as rheumatoid arthritis or metastatic colorectal cancer, establish no clinically meaningful differences in efficacy, safety, or immunogenicity.
For instance, Sandoz’s bevacizumab‑based biosimilar “Bevax” completed a randomized, double‑blind, non‑inferiority trial in 1,200 patients with metastatic colorectal cancer. The study reported a hazard ratio (HR) for progression‑free survival (PFS) of 1.02 (90 % CI 0.94–1.10), meeting the pre‑defined equivalence margin of ±15 %. Immunogenicity rates were below 1 % in both arms, aligning with the low‑immunogenicity profile expected for IgG1 monoclonal antibodies.
Regulatory Pathways and European Strategic Autonomy
The Lendava site strengthens Sandoz’s position within the European regulatory ecosystem. By concentrating manufacturing capabilities in the EU, the company enhances supply‑chain resilience, a priority identified by European health authorities in response to the COVID‑19 pandemic and global drug shortages. Moreover, the plant aligns with the European Commission’s “European Medicines Strategy” that emphasizes the development of autonomous production capacities for critical biologics.
The facility also supports compliance with the EU’s Good Manufacturing Practice (GMP) guidelines and the newly implemented GMP‑4.0 framework, which emphasizes risk‑based quality management and continuous monitoring. Sandoz’s integration of PAT into its manufacturing processes is consistent with the European Medicines Agency’s guidance on “Process Analytical Technology (PAT) and Quality by Design (QbD).”
Business Implications and Future Outlook
Sandoz’s expansion into Lendava is strategically positioned to capture increasing market demand for biosimilars. According to market analysts, the global biosimilar market is projected to reach €90 billion by 2035, driven by cost‑savings imperatives and expanding indications. By expanding its production footprint, Sandoz can meet regional demand more efficiently, reduce logistics costs, and enhance product availability for under‑served patient populations.
The company plans to host an investor and analyst visit to the Lendava facility in November. During this event, executives will provide a detailed overview of production metrics, including yield improvements, cost‑per‑dose reductions, and projected timelines for launching additional biosimilars under the Bio100 roadmap.
Conclusion
Sandoz Group AG’s new high‑volume manufacturing centre in Lendava represents a significant stride toward achieving its 2040 “Bio100” target. By marrying advanced process‑analytical technology with a robust regulatory framework, the company is poised to deliver high‑quality, affordable biosimilars that meet stringent safety and efficacy standards while reinforcing European strategic autonomy in biologics production.
